The FDA’s recent inclusion of certain GLP-1 receptor agonists on a so-called “Green List” is often portrayed as a regulatory milestone aimed at ensuring safer access to these increasingly popular medications. However, beneath the surface, this policy move may ironically serve to legitimize and even entrench a burgeoning gray market around GLP-1 drugs, with profound implications for patient safety, healthcare equity, and pharmaceutical regulation.
GLP-1 receptor agonists—originally designed to treat type 2 diabetes—have gained explosive popularity off-label, especially for weight management and metabolic health. This surging demand has outpaced formal channels of prescription and distribution, spawning widespread direct-to-consumer sales through unofficial websites, compounding pharmacies, and global online suppliers. Many patients seeking these medications face long waits, insurance denials, or high out-of-pocket costs, driving them toward these gray markets.
By creating a Green List that acknowledges certain GLP-1 products as “allowed” or “preferred,” the FDA ostensibly wants to direct patients and healthcare providers toward safer, vetted versions. Yet this approach has a major policy paradox: it simultaneously draws a tacit boundary between “approved” and “non-approved” products without substantially tightening enforcement against gray market purveyors. The list may inadvertently signal to consumers that purchasing from these green-listed sources is “acceptable,” while failing to diminish demand for unlisted or counterfeit alternatives, which often flourish in parallel.
Critically, this policy falls short of addressing the root drivers of the gray market. The FDA’s approach seems premised on the assumption that supply-side regulation—vetting which GLP-1 formulations can circulate—will curtail unsafe use. But the persistence of structural barriers—high costs, insurance hurdles, limited prescribing capacity—ensures ongoing gaps between demand and legitimate supply. As long as these systemic challenges remain unaddressed, the gray market will continue to thrive under a new guise of partial legitimacy.
Moreover, this FDA tactic risks creating a two-tiered system of access: patients with means or knowledge to navigate the Green List and secure recommended products, and others left vulnerable to unregulated, potentially unsafe alternatives. Rather than eliminate uncertainty, the policy may amplify confusion about product legitimacy and quality, undermining public trust.
The move also reveals a cautious regulatory posture that appears reactive rather than proactive. Instead of aggressively expanding legitimate access channels—such as through faster approvals for generics or innovative payment models—the FDA’s Green List acts as a stopgap, implicitly accepting gray market realities rather than confronting them head-on with comprehensive reforms.
In sum, while the FDA’s Green List for GLP-1 drugs aims to guide safer medication use, its limited scope and ambivalent enforcement risk reinforcing the very gray market it seeks to constrain. A more effective policy would integrate robust demand-side solutions, enhanced patient education, and stronger cross-border regulatory cooperation to ultimately dismantle unsafe supply chains rather than merely “legitimize” portions of the gray area. Without such broader reforms, the Green List may become a regulatory band-aid on an increasingly complex pharmaceutical access crisis.
About the Author: STACY FEILER— Retired—former Public Policy consultant company owner -Liberty Tree Consulting
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
